Edwards Lifesciences (EW) remains Canaccord's top pick in the medical technology sector, as the firm sees a number of catalysts for the companies in the sector when they report earnings over the next few weeks, but the firm is most positive on Edwards.
Canaccord expects commentary regarding Boston Scientific's (BSX) Lotus value to be positive for Edwards Lifesciences, and expects positive updates on EW's transcatheter mitral/ tricuspid technologies.
Edwards' stock was up slightly in early Monday afternoon trading.
(What will move markets this quarter and how should investors position themselves ahead of time? Jim Cramer sat down with four of TheStreet's top columnists recently to get their views. Click here to listen to his latest Trading Strategies roundtable with them and read their advice for stocks, bonds, forex and gold.)